1. The GRADE Evidence Evaluation System
All clinical protocols and practice recommendations on SafeInfusionTherapy.com are evaluated using the internationally recognized GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system:
| Evidence Level | Study Types & Sources | Editorial Weighting | Presentation on Site |
|---|---|---|---|
| GRADE Level A (High) | Multi-center RCTs, systematic reviews, CDC/INS/WHO practice guidelines | Primary clinical standard | Foundation of all practice protocols and algorithms |
| GRADE Level B (Moderate) | Prospective cohort studies, well-designed observational registries | Strong supporting evidence | Cited in comparative tables and clinical discussions |
| GRADE Level C (Low) | Case reports, single-center audits, expert committee consensus | Adjunctive consideration | Explicitly labeled as institutional consensus |
2. 12-Month Review Cycle & Commercial Independence
To preserve clinical integrity, our governance enforces two core policies:
- Mandatory 12-Month Review Cycle: Every clinical page is subjected to an exhaustive re-audit by our Medical Review Board at least once every 12 months, or within 30 days of major regulatory updates (e.g. FDA Black Box alerts or CDC guideline revisions).
- Strict Commercial Independence: We maintain a strict firewall separating editorial decisions from pharmaceutical manufacturers (e.g. Pfizer, Janssen) and medical device corporations (e.g. B. Braun, BD, ICU Medical, Baxter). We accept zero paid promotional placements or sponsored content.
- Transparent Corrections Policy: If a factual error is identified, our editorial board investigates within 24 hours. Verified corrections are published with a transparent revision notice within 48 hours.